Trials / Enrolling By Invitation
Enrolling By InvitationNCT06292533
Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study
- Status
- Enrolling By Invitation
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- Sponsor
- Universiti Tunku Abdul Rahman · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to to evaluate the effectiveness of Ultrapulse for the treatment of androgenic alopecia among Malaysian. The main questions it aims to answer are: * the efficacy of Ultrapulse in treatment of androgenic alopecia among Malaysian * the safety and adverse effect of Ultrapulse treatment. * the quality of life of androgenic alopecia among Malaysian.
Detailed description
Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle. It generates multiple micro pores at the epidermal layer that enhances the absorption of the active substances that help to stimulate hair growth developed by Lyzer Co. Ltd in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Er:YAG laser | Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle. |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-08-01
- Completion
- 2025-12-01
- First posted
- 2024-03-05
- Last updated
- 2024-12-18
Locations
1 site across 1 country: Malaysia
Source: ClinicalTrials.gov record NCT06292533. Inclusion in this directory is not an endorsement.